SKIN AND SOFT TISSUE INFECTIONS: Edited by Matteo BassettiCotrimoxazole and clindamycin in skin and soft tissue infectionsMontravers, Philippea,b,c; Eckmann, ChristiandAuthor Information aUniversité de Paris, UFR Denis Diderot bINSERM UMR 1152 cAnesthesiology and Critical Care Medicine, Bichat-Claude Bernard University Hospital, Pole PARABOL, AP-HP, Paris, France dDepartment of General, Visceral and Thoracic Surgery, Klinikum Hannoversch Muenden and Goettingen University, Muenden, Germany Correspondence to Philippe Montravers, Anesthesiology and Critical Care Medicine, CHU Bichat-Claude Bernard, 46 Rue Henri Huchard, 75018 Paris, France. Tel: +33140256024; e-mail: [email protected] Current Opinion in Infectious Diseases: April 2021 - Volume 34 - Issue 2 - p 63-71 doi: 10.1097/QCO.0000000000000698 Buy Metrics Abstract Purpose of review The aim of this study was to present recent microbiological, experimental, clinical and tolerance data for cotrimoxazole and clindamycin in the specific field of skin and soft tissue infections (SSTIs). Recent findings Staphylococcus aureus and streptococci remain the leading cause of SSTIs. Cotrimoxazole is a good anti-Gram-positive agent with preserved activity against methicillin-susceptible and methicillin-resistant S. aureus (MRSA) and streptococci. Although clindamycin has good methicillin-susceptible S. aureus activity, a growing number of resistant MRSA and streptococci have been reported. Strong experimental data support the antitoxin activity of clindamycin, but clinical observations remain scarce. Several recent randomized trials involving cotrimoxazole and/or clindamycin demonstrate the efficacy and tolerance of both drugs. The oral formulation of both drugs may facilitate the implementation of early switch and early discharge protocols in clinical practice. Summary Recent publications demonstrate that cotrimoxazole and clindamycin remain reliable and realistic therapeutic approaches for SSTIs. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.